At $0.74 Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Is Worth A Gamble
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares stood at 1.7 million during the last session, with the company’s beta value hitting 2.22. At the close
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares stood at 1.7 million during the last session, with the company’s beta value hitting 2.22. At the close
In the last trading session, 1.24 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.21. With the company’s per
In the last trading session, 0.87 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.22. With the company’s per
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) has a beta value of 2.21 and has seen 0.95 million shares traded in the recent trading session. The company,
During the last session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares were 1.98 million, with the beta value of the company hitting 2.22. At the
In today’s recent session, 0.45 million shares of the Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) have been traded, and its beta is 2.22. Most recently the
© 2024, Powered by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.